Related references
Note: Only part of the references are listed.Phase II, Open-Label Study of Brivanib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma
Joong-Won Park et al.
CLINICAL CANCER RESEARCH (2011)
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
Riccardo Lencioni et al.
SEMINARS IN LIVER DISEASE (2010)
A Multi-Institutional Phase II Study of the Efficacy and Tolerability of Lapatinib in Patients with Advanced Hepatocellular Carcinomas
Tanios Bekaii-Saab et al.
CLINICAL CANCER RESEARCH (2009)
Phase II Trial of the Combination of Bevacizumab and Erlotinib in Patients Who Have Advanced Hepatocellular Carcinoma
Melanie B. Thomas et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study
Andrew X. Zhu et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
EGFR and VEGFR as potential target for biological therapies in HCC cells
Gianlulgi Giannelli et al.
CANCER LETTERS (2008)
Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma
Abby B. Siegel et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Design and endpoints of clinical trials in hepatocellular carcinoma
Josep M. Llovet et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Angiopoietin-2 serum levels are elevated in patients with liver cirrhosis and hepatocellular carcinoma
Arne Scholz et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2007)
Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma
Melanie B. Thomas et al.
CANCER (2007)
Angiopoietin 2 displays a vascular endothelial growth factor dependent synergistic effect in hepatocellular carcinoma development in mice
H Yoshiji et al.
GUT (2005)
Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer
PA Philip et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Overexpression of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma
T Torimura et al.
JOURNAL OF HEPATOLOGY (2004)
Overexpression of VEGF and angiopoietin 2: A key to high vascularity of hepatocellular carcinoma?
WS Moon et al.
MODERN PATHOLOGY (2003)
Delayed gastrointestinal transit in patients with hepatocellular carcinoma
CY Chen et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2002)
Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo
IB Lobov et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Angiopoietin-2 is implicated in the regulation of tumor angiogenesis
Q Yu et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
Levels of circulating endothelin-1 and nitrates/nitrites in patients with virus-related hepatocellular carcinoma
G Notas et al.
JOURNAL OF VIRAL HEPATITIS (2001)
Share Paper
